.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Chinese Patent Office
Fuji
Baxter
Express Scripts
Covington
Deloitte
Johnson and Johnson
Queensland Health

Generated: November 22, 2017

DrugPatentWatch Database Preview

Osimertinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for osimertinib mesylate and what is the scope of osimertinib mesylate freedom to operate?

Osimertinib mesylate
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Osimertinib mesylate has seventy-three patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for osimertinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: osimertinib mesylate

Country Document Number Estimated Expiration
South Korea20140030089► Subscribe
Singapore194783► Subscribe
Denmark2736895► Subscribe
Uruguay34219► Subscribe
Dominican RepublicP2013000263► Subscribe
China104109151► Subscribe
South Korea101410902► Subscribe
China105348266► Subscribe
Canada2843109► Subscribe
Cyprus1117431► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
Colorcon
Baxter
McKinsey
Queensland Health
Daiichi Sankyo
QuintilesIMS
US Department of Justice
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot